Commonwealth Equity Services, LLC Axsome Therapeutics, Inc. Transaction History

Commonwealth Equity Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$57.42 - $83.61 $17,226 - $25,083	300 Added 4.45%	7,041 $560,000
Q3 2023 Oct 23, 2023	BUY	$69.25 - $82.21 $107,891 - $128,083	1,558 Added 30.06%	6,741 $471,000
Q2 2023 Aug 10, 2023	BUY	$58.41 - $90.35 $302,739 - $468,284	5,183 New	5,183 $372,000
Q4 2022 Feb 07, 2023	SELL	$39.94 - $79.72 $23,005 - $45,918	-576 Reduced 5.65%	9,624 $742,000
Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $53,116 - $102,889	-1,473 Reduced 12.62%	10,200 $455,000

Q2 2022 Jul 19, 2022	SELL	$21.74 - $46.75 $28,653 - $61,616	-1,318 Reduced 10.15%	11,673 $447,000
Q1 2022 May 04, 2022	SELL	$23.7 - $41.39 $94,634 - $165,270	-3,993 Reduced 23.51%	12,991 $537,000
Q4 2021 Jan 31, 2022	BUY	$30.7 - $43.36 $63,825 - $90,145	2,079 Added 13.95%	16,984 $641,000
Q3 2021 Oct 29, 2021	BUY	$19.91 - $68.26 $296,758 - $1.02 Million	14,905 New	14,905 $491,000

290

37.1M

401K

464K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.44B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.